| Q50541710 | A Developmental Toxicology Assay Platform for Screening Teratogenic Liability of Pharmaceutical Compounds. |
| Q60927377 | A colon-specific prodrug of metoclopramide ameliorates colitis in an experimental rat model |
| Q40626172 | A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis |
| Q72894394 | Amino acid derivatives of 5-ASA as novel prodrugs for intestinal drug delivery |
| Q33704930 | Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe |
| Q26741370 | Chronic haemorrhagic radiation proctitis: A review |
| Q37944771 | Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II). |
| Q39391912 | Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid |
| Q68326147 | Colchicine therapy of the renal amyloidosis of ulcerative colitis |
| Q41455884 | Colitis Is Effectively Ameliorated by (±)-8-Acetonyl-dihydrocoptisine via the XBP1-NF-κB Pathway |
| Q34086102 | Comparative tolerability of treatments for inflammatory bowel disease |
| Q74829293 | Cost, benefits and unintended gastrointestinal side effects of pharmaceutical therapy |
| Q77120985 | Current guidelines for the drug treatment of ankylosing spondylitis |
| Q36622124 | Current therapy of inflammatory bowel disease in children |
| Q91886286 | Cystine/Glutamate Antiporter (xCT) Is Required for Chief Cell Plasticity After Gastric Injury |
| Q70062946 | Deficient interleukin 2 production in rheumatoid arthritis: association with active disease and systemic complications |
| Q33186067 | Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid |
| Q46143029 | Development of IgA and IgG2 subclass deficiency after sulfasalazine therapy |
| Q42967651 | Dextran Carrier Macromolecules for Colon-specific Delivery of 5-Aminosalicylic Acid |
| Q43024839 | Drug rash with eosinophilia and systemic symptoms secondary to sulfasalazine |
| Q47803536 | Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers |
| Q33564950 | Evaluation of sulphasalazine in the treatment of spondyloarthropathies |
| Q40681801 | Fever, arthralgias, skin lesions, and ischemic digits in a 59‐year‐old man |
| Q71192065 | Fixed drug eruption induced by sulfasalazine |
| Q37481450 | Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs |
| Q33561832 | HLA types in patients with rheumatoid arthritis developing leucopenia after both gold and sulphasalazine treatment |
| Q28068832 | Implication of the intestinal microbiome in complications of cirrhosis |
| Q69880502 | Inflammatory bowel disease in pregnancy: a review |
| Q37437819 | Inflammatory bowel disease. Part II: Clinical and therapeutic aspects |
| Q36415031 | Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. |
| Q39328433 | Inhibition of SLC7A11 by Sulfasalazine Enhances Osteogenic Differentiation of Mesenchymal Stem Cells by Modulating BMP2/4 Expression and Suppresses Bone Loss in Ovariectomized Mice |
| Q46179598 | Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease |
| Q24804632 | Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis |
| Q36623918 | Lack of cross-reactivity between 5-aminosalicylic acid-based drugs: a case report and review of the literature |
| Q70049567 | Lack of effect of 5-aminosalicylic acid on platelet aggregation and fibrinolytic activity in vivo and in vitro |
| Q35546875 | Limited effect of sulphasalazine treatment in reactive arthritis. A randomised double blind placebo controlled trial |
| Q34273329 | Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis |
| Q34530593 | Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis |
| Q26865546 | Mesalamine in the treatment and maintenance of remission of ulcerative colitis |
| Q49487244 | Mesalazine as a cause of fetal anemia and hydrops fetalis: A case report |
| Q36832831 | Modulation of Apoptosis and Differentiation by the Treatment of Sulfasalazine in Rabbit Articular Chondrocytes |
| Q41313491 | Modulation of Gut Microbiome Composition and Function in Experimental Colitis Treated with Sulfasalazine |
| Q37114350 | N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy |
| Q41155743 | Neutropenia in patients with inflammatory arthritis treated with sulphasalazine |
| Q97523288 | Neutropenic Enterocolitis Secondary to Sulfasalazine in a Woman With Psoriatic Arthritis |
| Q68128172 | New enema treatments for inflammatory bowel disease |
| Q37598528 | New salicylate therapies for ulcerative colitis |
| Q51597109 | On-chip generation and reaction of unstable intermediates-monolithic nanoreactors for diazonium chemistry: azo dyes. |
| Q39465384 | Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease. An update |
| Q38203832 | Pediatric ulcerative colitis: a practical guide to management |
| Q46826559 | Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans |
| Q36110576 | Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. |
| Q51592243 | Pharmacokinetics of 5-aminosalicylic acid from controlled-release capsules in man |
| Q67773579 | Pharmacokinetics of 5-aminosalicylic acid in man following administration of intravenous bolus andper os slow-release formulation |
| Q64962071 | Polyunsaturated fat in the diet may improve intestinal function in patients with Crohn's disease. |
| Q64092514 | Probing the Solute-Solvent Interaction of an Azo-Bonded Prodrug in Neat and Binary Media: Combined Experimental and Computational Study |
| Q33914374 | Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease |
| Q40343068 | Promotion of Remyelination by Sulfasalazine in a Transgenic Zebrafish Model of Demyelination |
| Q46563091 | Protective effect of hawthorn fruit on murine experimental colitis |
| Q39448990 | Radiation proctitis: current strategies in management |
| Q37223156 | Renal effects of long-term treatment with 5-aminosalicylic acid |
| Q36502593 | Risk-Benefit Assessment of Drugs Used in the Treatment of Inflammatory Bowel Disease |
| Q34575542 | Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. |
| Q34723231 | Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group |
| Q33443950 | Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine |
| Q40557621 | Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine |
| Q72210433 | Sulfasalazine in atrophie blanche |
| Q46601924 | Sulfasalazine in the treatment of corticosteroid-dependent chronic idiopathic urticaria |
| Q41541658 | Sulphasalazine inhibition of human granulocyte activation by inhibition of second messenger compounds |
| Q36408869 | The Efficacy of Probiotic (Lactobacillus rhamnosus GG) and 5-ASA (Aminosalicylic Acid) in the Treatment of Experimental Radiation Proctitis in Rats |
| Q69905767 | The antiinflammatory moiety of sulfasalazine, 5-aminosalicylic acid, is a radical scavenger |
| Q89926938 | The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis |
| Q39691344 | The influence of nutrition on the systemic availability of drugs. Part II: Drug metabolism and renal excretion |
| Q33748043 | Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy |
| Q71668377 | Up-regulation of E-selectin and intercellular adhesion molecule-1 differs between Crohn's disease and ulcerative colitis |
| Q39470715 | Update on the aminosalicylates: a promise fulfilled. |
| Q34531409 | Use of colonic eicosanoid concentrations as predictors of relapse in ulcerative colitis: double blind placebo controlled study on sulphasalazine maintenance treatment |